You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Sumatriptan succinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for sumatriptan succinate and what is the scope of patent protection?

Sumatriptan succinate is the generic ingredient in eight branded drugs marketed by Meridian Medcl, Glaxosmithkline, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Sandoz, Steriscience Speclts, Sun Pharm, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Currax, Tonix Meds, Teva Branded Pharm, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in forty-one NDAs. There are thirty-two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan succinate has three hundred and eighty-two patent family members in thirty-one countries.

There are seventeen drug master file entries for sumatriptan succinate. Thirty-five suppliers are listed for this compound. There are four tentative approvals for this compound.

Summary for sumatriptan succinate
Drug Prices for sumatriptan succinate

See drug prices for sumatriptan succinate

Drug Sales Revenue Trends for sumatriptan succinate

See drug sales revenues for sumatriptan succinate

Recent Clinical Trials for sumatriptan succinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Second Affiliated Hospital of Kunming Medical UniversityPhase 3
Second Hospital of Jilin UniversityPhase 3
Beijing Friendship HospitalPhase 3

See all sumatriptan succinate clinical trials

Generic filers with tentative approvals for SUMATRIPTAN SUCCINATE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign UpEQ 100MG BASETABLET;ORAL
⤷  Sign Up⤷  Sign UpEQ 50MG BASETABLET;ORAL
⤷  Sign Up⤷  Sign UpEQ 25MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for sumatriptan succinate
Anatomical Therapeutic Chemical (ATC) Classes for sumatriptan succinate

US Patents and Regulatory Information for sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Roxane SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 078241-003 Aug 10, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Antares Pharma Inc SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 078319-002 Dec 10, 2015 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076933-002 Aug 10, 2009 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Parenteral SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 078318-001 Feb 6, 2009 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Inc SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076847-002 Aug 10, 2009 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tonix Meds ZEMBRACE SYMTOUCH sumatriptan succinate SOLUTION;SUBCUTANEOUS 208223-001 Jan 28, 2016 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for sumatriptan succinate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ⤷  Sign Up ⤷  Sign Up
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ⤷  Sign Up ⤷  Sign Up
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-002 Jun 1, 1995 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-001 Jun 1, 1995 ⤷  Sign Up ⤷  Sign Up
Endo Operations SUMAVEL DOSEPRO sumatriptan succinate INJECTABLE;SUBCUTANEOUS 022239-001 Jul 15, 2009 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-003 Jun 1, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for sumatriptan succinate

Country Patent Number Title Estimated Expiration
Canada 2748569 REGULATION ELECTRONIQUE D'UN SYSTEME DE DISTRIBUTION DE MEDICAMENT (ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM) ⤷  Sign Up
New Zealand 527760 Nasal devices ⤷  Sign Up
United Kingdom 2391482 Nasal devices ⤷  Sign Up
Portugal 1180378 ⤷  Sign Up
Japan 6992215 ⤷  Sign Up
Australia 2010202927 ⤷  Sign Up
Australia 2008358027 Pharmacokinetics of iontophoretic sumatriptan administration ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.